Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13 déc. 2021 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
22 nov. 2021 12h37 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
09 nov. 2021 06h45 HE
|
Cullinan Oncology, Inc.
Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021 Cullinan MICA and Cullinan Florentine programs to...
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
18 oct. 2021 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan” or “the Company”), a biopharmaceutical company focused on developing a diversified pipeline of...
Cullinan Oncology to Participate in Upcoming Investor Conferences
08 sept. 2021 16h01 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences: Morgan...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10 août 2021 06h30 HE
|
Cullinan Oncology, Inc.
Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology pipeline...
Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference
05 août 2021 16h05 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that it will be participating in the 41st Annual Canaccord Genuity Growth...
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
29 juin 2021 08h00 HE
|
Cullinan Oncology, Inc.
CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trialsCullinan will initiate a FIH trial in 3Q21, including a dose escalation cohort followed by dose expansion cohorts as a...
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
07 juin 2021 08h30 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
04 juin 2021 09h00 HE
|
Cullinan Oncology, Inc.
CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade 3 TRAE Diarrhea at Doses Below 150mg BID; No Grade 3...